Log in
Synthetic opioid analgesic

Fentanyl

Fentanyl is a highly potent synthetic opioid analgesic, approximately 50-100 times more potent than morphine. It is used for severe acute pain, chronic pain management, and as an adjunct in general anesthesia. The most testable fact is its high lipid solubility, enabling rapid onset and making it ideal for transdermal and transmucosal formulations.

Practice questionsHigh-yield facts
Drug classSynthetic opioid agonist (phenylpiperidine derivative)
MechanismMu-opioid receptor agonist in CNS and periphery
Main usesSevere pain, anesthesia adjunct, breakthrough cancer pain
Key adverse effectRespiratory depression, potentially fatal in overdose
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Fentanyl is a selective mu (μ) opioid receptor agonist. It binds to mu-opioid receptors located in the central nervous system (brain and spinal cord) and peripherally in the gastrointestinal tract. Activation of these G-protein coupled receptors leads to:

  • Inhibition of adenylyl cyclase, decreasing intracellular cAMP
  • Hyperpolarization of neurons via increased potassium efflux and decreased calcium influx
  • Reduced neurotransmitter release (substance P, glutamate) from nociceptive nerve terminals
  • Modulation of descending pain pathways in the central nervous system

These actions result in potent analgesia, euphoria, and sedation. Fentanyl's high lipid solubility allows rapid penetration of the blood-brain barrier, producing a faster onset of action compared to morphine (1-2 minutes intravenously). The lipophilicity also enables effective transdermal and transmucosal delivery, making it suitable for sustained-release patches and buccal/sublingual formulations.

High-yield for exams
  • Fentanyl is 50-100 times more potent than morphine; it is a synthetic mu-opioid receptor agonist
  • Highly lipophilic allowing rapid CNS penetration (onset 1-2 min IV) and transdermal delivery
  • Metabolized by CYP3A4; inhibitors like ketoconazole increase levels and risk respiratory depression
  • Respiratory depression is the most dangerous adverse effect; naloxone is the reversal agent
  • Transdermal patches reserved for opioid-tolerant patients only; 12-18 hour delay to therapeutic level
  • Chest wall rigidity (wooden chest) can occur with rapid high-dose IV bolus
  • Preferred over morphine in renal failure (no active metabolites) and hemodynamic instability (no histamine release)
  • Schedule II controlled substance with high abuse potential; chronic use causes tolerance and physical dependence

Indications

Fentanyl is indicated for:

Acute Pain Management

  • Perioperative analgesia as part of balanced anesthesia
  • Procedural sedation for invasive procedures
  • Severe acute pain in emergency settings (trauma, myocardial infarction)

Chronic Pain Management

  • Chronic severe pain requiring continuous opioid analgesia in opioid-tolerant patients
  • Cancer pain, particularly via transdermal patches for baseline control
  • Breakthrough cancer pain using rapid-onset transmucosal formulations (buccal tablets, sublingual tablets, nasal spray)

Anesthesia

  • Adjunct to general anesthesia for induction and maintenance
  • Component of neuraxial anesthesia (epidural, spinal) for labor analgesia and postoperative pain

Transdermal fentanyl patches are reserved for opioid-tolerant patients with chronic pain; they are not appropriate for acute or intermittent pain due to their delayed onset and prolonged duration.

Pharmacokinetics

Absorption

  • Intravenous: immediate bioavailability, onset within 1-2 minutes
  • Transdermal: slow absorption through skin, steady-state reached in 12-24 hours; first patch takes 12-18 hours to reach therapeutic levels
  • Transmucosal (buccal, sublingual, intranasal): rapid absorption through oral mucosa, onset 5-15 minutes
  • Oral: extensive first-pass metabolism, bioavailability only 30-50%

Distribution

  • Highly lipophilic, rapidly redistributes into fat and muscle
  • Volume of distribution approximately 4 L/kg
  • Protein binding 80-85% (primarily alpha-1-acid glycoprotein)
  • Crosses placenta and appears in breast milk

Metabolism

  • Primarily hepatic via CYP3A4 to norfentanyl (inactive metabolite)
  • No active metabolites
  • Extensive first-pass effect limits oral bioavailability

Elimination

  • Elimination half-life: 2-4 hours after IV bolus; 17-25 hours after transdermal patch removal (due to continued absorption from skin depot)
  • Excreted primarily in urine (75% as metabolites, <10% unchanged)
  • Context-sensitive half-time increases with prolonged infusions due to accumulation in peripheral tissues

Adverse effects

Central Nervous System

  • Respiratory depression — dose-dependent, potentially fatal; most dangerous adverse effect
  • Sedation and drowsiness
  • Dizziness and confusion, particularly in elderly
  • Miosis (pinpoint pupils)
  • Seizures (at very high doses due to accumulation of metabolites or direct effect)

Gastrointestinal

  • Constipation — occurs in most patients due to mu-receptor activation in GI tract
  • Nausea and vomiting (30-50% of patients)
  • Delayed gastric emptying
  • Dry mouth

Cardiovascular

  • Bradycardia from vagal stimulation
  • Hypotension, especially with rapid IV administration
  • Chest wall rigidity with rapid high-dose IV administration (can impair ventilation)

Other

  • Pruritus (itching), particularly with neuraxial administration
  • Urinary retention
  • Tolerance and physical dependence with chronic use
  • Hyperalgesia (increased pain sensitivity) with prolonged high-dose use
  • Sweating

Black Box Warnings

  • Respiratory depression and death, especially in opioid-naive patients
  • Accidental exposure, particularly in children (fatal with patches or lozenges)
  • Cytochrome P450 3A4 interaction leading to increased fentanyl levels
  • Neonatal opioid withdrawal syndrome with prolonged maternal use
  • Transdermal patches reserved for opioid-tolerant patients only

Contraindications and warnings

Absolute Contraindications

  • Hypersensitivity to fentanyl or other opioids
  • Acute or severe asthma in unmonitored settings or without resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Transdermal fentanyl contraindicated in:
  • Opioid-naive patients
  • Acute or postoperative pain
  • Mild or intermittent pain responsive to other analgesics

Warnings and Precautions

  • Respiratory conditions: COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia
  • Head injury or increased intracranial pressure: may obscure neurologic assessment and increase CO2 retention
  • Hepatic impairment: reduced metabolism increases risk of accumulation
  • Renal impairment: metabolites may accumulate
  • Elderly patients: increased sensitivity to respiratory depression
  • Pregnancy category C: crosses placenta; chronic use can cause neonatal withdrawal syndrome
  • Lactation: excreted in breast milk; monitor infant for sedation and respiratory depression
  • Heat exposure with transdermal patches: increased absorption from vasodilation (fever, heating pads, hot baths)
  • Risk of abuse, addiction, and diversion — Schedule II controlled substance in the US

Drug interactions

CYP3A4 Inhibitors

Increase fentanyl levels, potentially causing fatal respiratory depression:

  • Azole antifungals (ketoconazole, itraconazole)
  • Macrolide antibiotics (erythromycin, clarithromycin)
  • Protease inhibitors (ritonavir, indinavir)
  • Grapefruit juice
  • Diltiazem, verapamil

Dose reduction or closer monitoring required.

CYP3A4 Inducers

Decrease fentanyl levels, reducing efficacy:

  • Rifampin, rifabutin
  • Carbamazepine, phenytoin, phenobarbital
  • St. John's wort

May require dose increase or alternative therapy.

CNS Depressants

Additive respiratory depression and sedation:

  • Benzodiazepines (midazolam, diazepam) — FDA black box warning for combined use
  • Alcohol
  • Other opioids
  • Sedative-hypnotics (zolpidem, eszopiclone)
  • Barbiturates
  • General anesthetics
  • Gabapentinoids (gabapentin, pregabalin)

Serotonergic Drugs

Risk of serotonin syndrome when combined with:

  • SSRIs, SNRIs
  • MAO inhibitors (particularly within 14 days)
  • Tricyclic antidepressants
  • Triptans
  • Linezolid

Other Interactions

  • Muscle relaxants: enhanced neuromuscular blockade
  • Anticholinergic drugs: increased risk of urinary retention and severe constipation
  • Naloxone and naltrexone: opioid antagonists reverse fentanyl effects

Clinical pearls

  • Fentanyl is 50-100 times more potent than morphine by weight; equianalgesic dosing must account for this difference to avoid overdose.
  • The rapid onset (1-2 minutes IV) and short duration (30-60 minutes after single dose) make fentanyl ideal for procedural sedation and titration during anesthesia, but repeated dosing or infusions lead to accumulation and prolonged effects.
  • Transdermal patches provide sustained analgesia for 48-72 hours but have a 12-18 hour lag before therapeutic levels are reached; supplemental short-acting opioids are needed initially. Heat increases absorption from patches.
  • Chest wall rigidity (wooden chest syndrome) can occur with rapid high-dose IV administration, especially during anesthesia induction. This can severely impair ventilation and may require muscle relaxants and mechanical ventilation.
  • Naloxone is the antidote for fentanyl overdose. Due to fentanyl's high potency, multiple naloxone doses or continuous infusion may be required. Intranasal naloxone is available for community use.
  • Fentanyl has minimal hemodynamic effects compared to morphine (which releases histamine) and is preferred in hemodynamically unstable patients.
  • Breakthrough cancer pain formulations (buccal, sublingual, intranasal) are dosed independently of baseline opioid regimens and are not interchangeable; each formulation requires separate titration.
  • Tolerance develops rapidly with continuous use; patients on chronic opioid therapy require higher doses. Physical dependence is expected with prolonged use and is distinct from addiction.
  • In renal failure, fentanyl is preferred over morphine because it has no active metabolites that accumulate and cause toxicity (morphine-6-glucuronide).
  • The lipophilicity of fentanyl results in significant tissue redistribution, creating a reservoir that prolongs elimination after chronic dosing, infusions, or transdermal use (context-sensitive half-time increases dramatically).

Practice questions

1. A 68-year-old man with metastatic prostate cancer has been receiving transdermal fentanyl patches 50 mcg/hr every 72 hours for baseline pain control. He develops a fever of 39°C (102.2°F) and becomes increasingly sedated with a respiratory rate of 8 breaths per minute. Which of the following best explains his presentation?

Answer: B. Fever increases skin temperature and blood flow, significantly enhancing transdermal fentanyl absorption from the patch reservoir, leading to higher serum levels and respiratory depression. This is a well-recognized complication requiring patch removal and supportive care. Fentanyl has no active metabolites that accumulate, and acute tolerance would decrease rather than increase effects. CYP3A4 induction would decrease fentanyl levels.

2. A 45-year-old woman undergoing laparoscopic cholecystectomy receives a rapid IV bolus of fentanyl 200 mcg during anesthesia induction. Within 30 seconds, the anesthesiologist notes the patient has become difficult to ventilate despite adequate mask seal and airway positioning. Oxygen saturation drops to 88%. Blood pressure is 110/70 mmHg. What is the most likely cause of impaired ventilation?

Answer: C. Rapid high-dose fentanyl bolus causes chest wall rigidity (wooden chest syndrome) by inducing tonic contraction of thoracic and abdominal muscles, making ventilation extremely difficult. This is a classic complication during anesthesia induction requiring muscle relaxants and continued mechanical ventilation. Unlike morphine, fentanyl does not cause significant histamine release. The stable blood pressure and rapid onset make the other options less likely.

3. A 58-year-old man with chronic back pain on transdermal fentanyl is started on clarithromycin for community-acquired pneumonia. Three days later, he is brought to the emergency department with confusion, pinpoint pupils, and a respiratory rate of 6 breaths per minute. Which mechanism best explains this patient's condition?

Answer: C. Clarithromycin is a potent CYP3A4 inhibitor that reduces fentanyl metabolism, causing accumulation and opioid toxicity manifesting as respiratory depression and altered mental status. This is a black box warning interaction requiring dose adjustment or alternative antibiotics. Macrolides do not have direct respiratory depressant effects, and fentanyl has no active metabolites. The clinical picture is classic for opioid overdose from a drug interaction rather than hepatotoxicity.

Frequently asked questions

How does fentanyl work?

Fentanyl works by binding to mu-opioid receptors in the brain and spinal cord, inhibiting pain signal transmission and producing analgesia. It is a highly potent synthetic opioid approximately 50-100 times stronger than morphine. Its high lipid solubility allows rapid penetration into the central nervous system, resulting in quick onset of pain relief within 1-2 minutes when given intravenously.

What are the side effects of fentanyl?

The most serious side effect of fentanyl is respiratory depression, which can be fatal in overdose. Common side effects include constipation (occurring in most patients), nausea, vomiting, drowsiness, dizziness, and confusion. Other effects include pinpoint pupils, itching, urinary retention, and bradycardia. Rapid intravenous administration can cause chest wall rigidity that impairs breathing. Chronic use leads to tolerance and physical dependence.

Is fentanyl a controlled substance?

Yes, fentanyl is a Schedule II controlled substance in the United States due to its high potential for abuse, addiction, and diversion. It requires a written prescription from a licensed prescriber (some states allow electronic prescriptions), and refills are not permitted. The DEA strictly regulates its manufacture, distribution, and prescribing. Illicitly manufactured fentanyl is a major contributor to opioid overdose deaths.

What is the difference between fentanyl and morphine?

Fentanyl is a synthetic opioid that is 50-100 times more potent than morphine by weight. Fentanyl has faster onset (1-2 minutes versus 5-10 minutes IV), shorter duration after single doses, and greater lipid solubility enabling transdermal delivery. Unlike morphine, fentanyl does not release histamine, making it preferable in hemodynamically unstable patients. Fentanyl is metabolized to inactive compounds, while morphine produces morphine-6-glucuronide that accumulates in renal failure, making fentanyl safer in kidney disease.

Can fentanyl patches be used for acute pain?

No, fentanyl patches are contraindicated for acute pain management. Transdermal fentanyl has a delayed onset of 12-18 hours before reaching therapeutic blood levels and provides sustained analgesia over 48-72 hours. They are approved only for chronic pain in opioid-tolerant patients who require continuous around-the-clock analgesia. Using patches for acute or postoperative pain can cause fatal respiratory depression due to inappropriate dosing and accumulation.

Conditions it is used for

Severe acute painChronic cancer painBreakthrough painPostoperative painProcedural painLabor painMyocardial infarction painTrauma pain
MorphineHydromorphoneOxycodoneRemifentanilSufentanilAlfentanilMethadoneNaloxone

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N01AH01WHO ATC/DDD index: N02AB03

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.